Silverstein Jordyn, Smick Alexandra, Johnson Bridget, Konecny Gottfried E
Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, USA.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Los Angeles, CA, USA.
Future Oncol. 2025 Jul;21(17):2143-2153. doi: 10.1080/14796694.2025.2513848. Epub 2025 Jun 12.
Mirvetuximab soravtansine (MIRV) is FDA-approved for platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression. In the MIRASOL trial, MIRV improved median progression-free survival (5.6 vs. 3.9 months) and overall survival (16.5 vs. 12.8 months; HR 0.67) over chemotherapy. MIRV has a favorable safety profile but is associated with unique ADC-related toxicities, including blurred vision, keratopathy, and nausea. Ocular side effects are managed with regular eye exams and prophylactic drops, with no permanent damage reported. MIRV has also shown promising results in combination with bevacizumab and with carboplatin in platinum-sensitive disease. Ongoing research aims to optimize ADC components and explore synergistic combinations to expand MIRV's role in FRα-expressing ovarian cancer.
mirvetuximab soravtansine（MIRV）已获美国食品药品监督管理局（FDA）批准，用于治疗叶酸受体α（FRα）高表达的铂耐药卵巢癌。在MIRASOL试验中，与化疗相比，MIRV改善了中位无进展生存期（5.6个月对3.9个月）和总生存期（16.5个月对12.8个月；风险比[HR]为0.67）。MIRV具有良好的安全性，但与独特的抗体药物偶联物（ADC）相关毒性有关，包括视力模糊、角膜病变和恶心。通过定期眼科检查和预防性滴眼液来处理眼部副作用，未报告有永久性损伤。MIRV与贝伐单抗联合以及与卡铂联合用于铂敏感疾病也显示出有前景的结果。正在进行的研究旨在优化ADC组件并探索协同组合，以扩大MIRV在FRα表达的卵巢癌中的作用。
